Navigation Links
Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that it has signed an exclusive agreement with WILEX AG for commercialization rights in the United States for RENCAREX® (girentuximab).  RENCAREX® is a Phase III product candidate for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC).

Under the terms of the agreement, WILEX will receive $19.0 million upfront payments and development fees plus milestone payments and royalties on U.S. net sales of RENCAREX®.  In addition, Prometheus will co-fund a portion of the ongoing development of RENCAREX®. The deal terms also include an agreement whereby WILEX may be granted commercialization rights outside of the United States, including but not limited to Europe, to one of Prometheus' marketed products or receive additional cash payments of up to $20 million.

Professor Olaf G. Wilhelm, Chief Executive Officer of WILEX, commented, "This is the deal we have been looking for, not only in financial, but also in commercial and strategic terms. We are very excited about WILEX'S new partnership with Prometheus since Prometheus has a proven track record in commercializing pharmaceutical and diagnostic products."

"We are very pleased to enter into this partnership with WILEX as we continue to build our oncology franchise," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "RENCAREX® is a great strategic fit with our current oncology portfolio in renal cell carcinoma. There is no product currently approved in the United States for patients who could have recurrence of ccRCC after a kidney resection.  We look forward to working with WILEX to complete the development process and commercialize RENCAREX® in the United States."

About RENCAREX®

RENCAREX® (girentuximab) is a highly specific chimeric monoclonal antibo
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
8. Prometheus Highlights Record Performance in 2010
9. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
10. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
11. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... to March 24 article in the ... Medicine ALEXANDRIA, Va. and JACKSONVILLE, Fla., March 24 ... New England Journal of Medicine suggests that intensive ... hyperglycemia (high blood glucose) does not improve outcomes and ...
... of concept for company,s first-in-class SERM designed to ... hormone therapy--CAMBRIDGE, Mass., March 24 Radius Health ... been dosed in the company,s proof-of-concept Phase 2a ... modulator (SERM) undergoing clinical evaluation for treatment of ...
Cached Medicine Technology:Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 2Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 3Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 4Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 2Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 3
(Date:5/24/2013)... (PRWEB) May 24, 2013 Gift ... Cards, major competitors in sustainable card material, are ... using forest materials as a sustainable gift card ... to identify industry challenges and increase education and ... programs to support the reduction of carbon footprint ...
(Date:5/24/2013)... respected Alzheimer,s researchers failed to replicate what appeared to ... disease when they were published last year in the ... Feb. 9, 2012, suggested that the drug bexarotene (marketed ... amyloid plaques (Aβ) a pathological hallmark of Alzheimer,s ... the authors of the 2012 report, drug treatment quickly ...
(Date:5/24/2013)... 2013 Mr. Brian Su, CEO of ... EB-5 Investment Summit: Dealmakers Conference in Long Beach, California ... on exploring alternative finance through EB-5 immigrant investors program. ... economic information, and updates to project developers, regional center ... , "Our goal is to assist EB-5 projects ...
(Date:5/24/2013)... 24, 2013 Mike Stoler believes that ... successful business people in New York. That’s why ... weekly on CUNY TV. And that’s why he ... Allergy Associates, LLP (ENTA)—the largest single specialty practice in ... throat, allergy and audiology specialists and sub-specialists service communities ...
(Date:5/24/2013)... to the National Institutes of Health, Stevens Johnson Syndrome (SJS) ... the skin and mucous membranes. SJS occurs most commonly ... (i). In the early stages SJS presents flu-like symptoms, ... it affects the mucous membranes such as the eyes, mouth ... eye causes conjunctivitis (pink eye). Inflammation of the mouth ...
Breaking Medicine News(10 mins):Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Brian Su Organizes 3rd Annual EB-5 Investment Conference in Long Beach, California 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3
... ... , ... 2009 -- Exercise is a critical piece of a healthy lifestyle, however, those who suffer ... January/February 2010 issue of Sports Health: A Multidisciplinary Approach. Authors confirm that exercise can aid ...
... At only 5-years ... Television and News shows including The Oprah Winfrey Show and Good morning America, Julian Pavone ... double kick. , ... 29, 2009 -- As a traveling Rock Star at such a young tender age, Julian’s ...
... ... Care Act , ... over 2000 pages contained within HR 3200, the House Bill that the recently passed Senate ... Americans thanks to a cooperative effort between Hearthebill.org and iScroll , developers of the ...
... , MOUNT PROSPECT, Ill., Dec. 28 On ... (NABP(R)) reached a bitter-sweet milestone in its ongoing review of ... 5,000 Internet drug outlets as Not Recommended. These sites -- ... been found to be out of compliance with pharmacy laws ...
... Germ linked to tooth decay evolved from a beneficial organism, ... research provides insights into the genetic makeup of a germ ... a great job of colonizing the mouth. , The ... related germs are best known for sitting in the gut ...
... , , , BIRMINGHAM, Ala., Dec. ... M.D., has some simple resolutions and fun advice for ... a board-certified clinical lipidologist (NLA), certified hypertension specialist (ASH), ... in Sandy, Utah, and Chief Medical Officer at Atherotech, ...
Cached Medicine News:Health News:Exercise May Reduce the Complications of Diabetes, According to Sports Health Journal Study 2Health News:Exercise May Reduce the Complications of Diabetes, According to Sports Health Journal Study 3Health News:Life Ionizers Drums to a New Beat with Julian Pavone, the Worlds Youngest Drummer and Inventor 2Health News:House Health Care Bill Becomes Up To 38% More Understandable 2Health News:5,000 Web Sites Selling Prescription Drugs Outside of Pharmacy Laws and Practice Standards 2Health News:5,000 Web Sites Selling Prescription Drugs Outside of Pharmacy Laws and Practice Standards 3Health News:Heart-Healthy ABC's for 2010 2
... two staggered eyes. It is made ... adapter is enclosed. They are color ... right. They are for single use, ... length is 65cm and they are ...
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
... RiteCut Right Angle Cutting Electrode is ... with a general purpose monopolar electrosurgical ... with any ACMI rigid, semi-rigid, or ... has a working channel larger than ...
Medicine Products: